0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mymetics
Its shares trade under the ticker MYMX. It has been listed since 10 February 1995. In the fiscal year to 31 December 2023, it reported revenue of €6,000 and a net loss of €11.6m.
Mymetics Corp. is a biotechnology company, which engages in the research and development of virosome based vaccines. The company is headquartered in Epalinges, Vaud. The firm is focused on developing vaccines for infectious diseases. The firm has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Feb 1995
- Employees
- 8
- Website
- mymetics.com ↗
Leadership
Pay as last reported
- Mr. Ronald KempersPresident, Chief Executive Officer, Chief Financial Officer$282,000
- Dr. Sylvain FleuryChief Scientific Officer, since 2003$282,000
- Mr. Ulrich BurkhardDirector
- Mr. Marcel RueggIndependent Director
- Dr. Thomas StaehelinIndependent Director$10,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a focused research and development approach in virosome based vaccines.
- The firm has over five vaccine candidates in its pipeline including HIV-1/AIDS, Influenza, Malaria, Herpes, and RSV.
- Technology utilizes virosomes, lipid-based carriers with functional fusion viral proteins and natural membrane proteins.
Weaknesses
- Company employs only 8 full-time employees.
- The company has not yet commercialized any vaccine candidates.
- The company's IPO was in 1995, indicating a long history without significant market presence.
Opportunities
- The pipeline includes multiple high-need disease areas such as HIV-1/AIDS and RSV.
- Virosome technology offers a novel approach for vaccine development.
- Potential for partnerships with larger pharmaceutical companies for vaccine development.
Threats
- The biotechnology sector is highly competitive with many established players.
- Long development timelines for vaccine candidates may delay market entry.
- Regulatory hurdles for vaccine approval could impact timeline and success.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.